Colombia Wound Care Biologics Market Analysis & Forecast: 2026-2033
Colombia Wound Care Biologics Market Analysis & Forecast: 2026-2033
Colombia Wound Care Biologics Market, By Product Type (Biologic Skin Substitutes, Enzyme Based Formulations), By Application (Chronic Wounds (Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer), Acute Wounds (Surgical Wounds, Burns)), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Colombia Wound Care Biologics Market Size and Share Analysis - 2026 To 2033
The Colombia wound care biologics market size is anticipated to grow at a CAGR of 10.2% with USD 15 Mn in 2026 and is expected to reach USD 29.5 Mn in 2033. The growth is mainly owing to rising chronic wound cases, especially diabetic foot ulcers, and increasing use of biologic skin substitutes, enzyme-based formulations, and growth-factor therapies. For instance, Colombia reported 3,033,800 adults with diabetes in 2024, thus creating a larger at-risk patient pool and facilitating wider adoption of advanced wound-healing solutions.
Key Takeaways
The biologic skin substitutes segment is projected to account for the largest share of 54.20% in 2026. The segment growth is due to the rising use of advanced tissue-regeneration products for diabetic foot ulcers, pressure ulcers, and non-healing wounds. IDF reported 3.0 Mn adults with diabetes in Colombia in 2024.
The chronic wounds segment is projected to account for the largest share of 68.40% in 2026. The segment’s growth is due to the increasing diabetes-related wound complications and the need for longer-duration wound care. IDF reported 8.4% adult diabetes prevalence in Colombia in 2024.
The hospitals segment is projected to account for the largest share of 44.30% in 2026. The growth is owing to hospitals being the primary setting for severe wounds, burns, surgical wounds, and advanced biologic applications. OECD reported 1.9 hospital beds per 1,000 population in Colombia.
On the basis of product type, the biologic skin substitutes segment accounts for the largest Colombia wound care biologics market share of 54.20% in 2026. The growth of the segment is mainly driven by the Colombia’s expanding chronic wound treatment need, especially among patients with diabetes, vascular ulcers, pressure ulcers, and post-surgical wounds.
These products are preferred in difficult-to-heal wounds because they act as extracellular matrix scaffolds, support tissue regeneration, and help clinicians manage wounds that do not respond to conventional dressings. The segment also benefits from Colombia’s stronger focus on cardiometabolic disease management, as the Ministry of Health emphasizes continuity of care, diabetes control, risk monitoring, patient education, and early intervention for complications.
In July 2024, INVIMA granted sanitary registration for InnovaMatrix AC Placental ECM to ConvaTec Colombia for import and sale, supporting access to an advanced biologic matrix indicated for diabetic ulcers, venous ulcers, pressure ulcers, chronic vascular ulcers, surgical wounds, burns, and trauma wounds.
Chronic Wounds Segment to Secure the Largest Share
On the basis of application, the chronic wounds segment accounts for the largest Colombia wound care biologics market share of 68.40% in 2026, owing to the rising diabetic population and higher need for advanced treatment of slow-healing ulcers. The segment is further driven by increasing use of biologic skin substitutes and regenerative membranes for diabetic foot ulcers, pressure ulcers, venous leg ulcers, and other long-duration wounds.
Colombia’s Cuenta de Alto Costo reported 2,597,719 diabetes mellitus cases as of August 31, 2025, creating a large patient base vulnerable to chronic wound complications. It also reported that only 44.02% of diabetes patients had HbA1c measurement information in the previous six months, thereby indicating gaps in glycemic monitoring that may increase non-healing wound risk.
Hospitals Segment to Secure the Largest Share
On the basis of end user, the hospitals segment accounts for the largest share of 44.30% in 2026. The segment’s growth is owing to the strong role of hospitals and institutional health providers in treating complex wounds, including diabetic foot ulcers, pressure ulcers, burns, venous ulcers, and post-surgical wounds. These cases often need physician-led wound assessment, debridement, infection control, biologic dressing selection, and regular monitoring.
Colombia’s SISPRO reported 19,682 IPS provider sites, which shows a broad institutional base for advanced wound care delivery. The SISPRO also reported 3,641 public IPS sites and 15,977 private IPS sites, thus facilitating hospital and clinic-based access to specialized treatment.
A relevant 2026 development is Colombia’s implementation of interoperable electronic health records from April 15, 2026, which may improve continuity of wound care between hospitals, clinics, and follow-up providers.
Market Drivers
Rising Chronic Wound Burden is Transforming the Colombia Wound Care Biologics Market
Rising chronic wound burden is transforming the Colombia wound care biologics market because hospitals and wound care centers are increasingly treating diabetic foot ulcers, venous leg ulcers, pressure injuries, burns, and complex surgical wounds with advanced regenerative products.
According to Colombia’s Ministry of Health, 1,985,748 people were living with diabetes mellitus during July 2022 to June 2023, representing a crude prevalence of 3.82 per 100 inhabitants. This directly expands the patient pool at risk of non-healing wounds and diabetic foot complications. For example, the country’s National Nutrition Situation Survey reported that 56.4% of adults had excess weight. This included 37.7% who were overweight and 18.7% who had obesity, thereby increasing the risk of delayed wound healing.
A relevant development is RegenCol’s collagen membrane, developed with UNAL support and registered with INVIMA, which entered initial commercialization through 2023 sales and alliances, supporting local adoption of biologic wound coverage solutions in Colombia.
A Major Breakthrough in the Colombia Wound Care Biologics Market: Stem Cell–Derived Biologics for Diabetic Foot Ulcers
Stem cell–derived biologics are becoming important in the Colombia wound care biologics market because diabetic foot ulcers require therapies that support tissue repair, angiogenesis, and faster wound closure.
The country’s Cuenta de Alto Costo reported that 2,597,719 people had diabetes mellitus as of August 2025. This creates a large patient base at risk of diabetic foot ulcers as well as delayed wound healing. It also reported that only 44.02% of people with diabetes had HbA1c measurement information in the last six months, thereby showing a monitoring gap which can increase the risk of uncontrolled diabetes along with chronic wound complications. Such factors are driving the Colombia wound care biologics market growth.
A new medical update is the ClinicalTrials.gov study NCT07553468, posted in April 2026. The study looks at stromal vascular fraction cells for diabetic foot ulcers and shows the move toward patient’s own cell-based treatments for wounds that do not improve with usual treatment.
Current Events and Their Impact on the Colombia Wound Care Biologics Market
Current Event
Description and its Impact
UDI-DI and Medical Device Traceability Requirements by INVIMA in Colombia (2026)
Description: Colombia is strengthening the traceability of medical devices through the UDI-DI coding and semantic standard under Resolution 1405 of 2022. INVIMA states that the measure supports identification, traceability, and regulatory surveillance of medical devices and diagnostic technologies. This is relevant for advanced wound care biologics, especially biologic skin substitute-related products and wound care technologies classified under medical device pathways.
Impact: The new traceability requirements may increase documentation, registration, labeling, and compliance responsibilities for manufacturers and importers. This could temporarily slow product approvals or commercialization for advanced wound healing products. However, stronger product identification and post-market monitoring are expected to improve hospital confidence, reduce counterfeit or poorly documented products, and support safer adoption of biologic wound care products in Colombia.
Colombia’s 2026 Health Financing and UPC Adjustment for the National Health System
Description: Colombia’s Ministry of Health increased the 2026 Unidad de Pago por Capitación (UPC), with a 9.03% increase for the contributory regime and 16.49% for the subsidized regime. The UPC is the per-capita payment used to finance health services covered under Colombia’s health system. This policy directly affects hospitals, clinics, and EPS purchasing capacity for wound care therapies.
Impact: Higher UPC funding may support broader treatment access for chronic wounds, diabetic foot ulcers, pressure ulcers, burns, and surgical wounds, especially in public and subsidized patient groups. However, financial pressure on EPS and hospitals may still restrict rapid adoption of premium biologic skin substitutes and growth-factor therapies. As a result, suppliers may need stronger clinical evidence, cost-effectiveness data, and hospital-level value propositions to improve procurement acceptance.
The rising diabetes burden in Colombia is increasing demand for biologic skin substitutes, growth factors, and regenerative wound care products used for diabetic foot ulcers and delayed wound healing. IDF reported 3,033,800 adults with diabetes in Colombia in 2024, representing 8.4% adult prevalence.
Hospitals and specialty clinics are increasingly adopting advanced wound-healing products because chronic wounds require longer treatment cycles, infection control, tissue regeneration, and faster closure support.
Biologic wound care adoption is supported by regulatory recognition of tissue-based products. INVIMA classified EPIFAST as a biological dressing and allograft derived from human tissue, showing relevance for biologic wound treatment pathways in Colombia.
Colombia’s medical device traceability rules are strengthening product monitoring. INVIMA states that UDI-DI coding under Resolution 1405 of 2022 improves identification, traceability, and safety of medical devices.
Public health financing may improve access to advanced wound care products, as Colombia’s 2026 UPC policy finances health services and technologies under the contributory and subsidized regimes.
Who are the Major Companies in Colombia Wound Care Biologics Market
Some of the major key players in Colombia wound care biologics market are Smith & Nephew, Plc, Organogenesis, Inc., Integra Life Sciences Corporation, MiMedx Group, Inc., Skye Biologics, Inc., Amino Technology LLC, Osiris Therapeutics, Inc., Alphatec Holdings, Inc. Mallinckrodt Plc., Amniox Medical, Inc., Acelity L.P. Inc., ConvaTec Group Plc, Generex Biotechnology Corporation, and Olaregen Therapeutix Inc.
Key News
In February 2026, Oneness announced that Bonvadis® topical cream received medical device marketing authorization from INVIMA Colombia. The approval covers all wound-related indications and allows the product to be marketed in Colombia as a wound dressing. The product was approved under the imported registration license number INVIMA2026DM-0032092.
In September 2025, Smith+Nephew launched the CENTRIO Platelet-Rich-Plasma (PRP) System in the U.S. for chronic exuding wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and tunneling wounds. The launch highlights growing adoption of biologic, autologous wound-healing solutions, which may influence advanced wound care practices in markets such as Colombia once local regulatory and commercial availability expands.
Market Report Scope
Colombia Wound Care Biologics Market Report Coverage
Report Coverage
Details
Base Year:
2025
Market Size in 2026:
USD 15 Mn
Historical Data for:
2020 To 2024
Forecast Period:
2026 To 2033
Forecast Period 2026 to 2033 CAGR:
10.2%
2033 Value Projection:
USD 29.5 Mn
Segments covered:
By Product Type: Biologic Skin Substitutes, Enzyme Based Formulations
By Application: Chronic Wounds (Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer), Acute Wounds (Surgical Wounds, Burns)
By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings
Companies covered:
Smith & Nephew, Plc, Organogenesis, Inc., Integra Life Sciences Corporation, MiMedx Group, Inc., Skye Biologics, Inc., Amino Technology LLC, Osiris Therapeutics, Inc., Alphatec Holdings, Inc. Mallinckrodt Plc., Amniox Medical, Inc., Acelity L.P. Inc., ConvaTec Group Plc, Generex Biotechnology Corporation, and Olaregen Therapeutix Inc.
Growth Drivers:
Increasing prevalence of diabetes and diabetic foot
Rising medical tourism, favoring the demand for wound care biologic products,
New product launches and approvals
Rising research and development activities for the development of novel technology for the treatment of wound
Restraints & Challenges:
Increasing adoption of alternative wound care products
The Colombia wound care biologics market is growing because chronic wound treatment is becoming a direct clinical need. Colombia reported 2,597,719 diabetes mellitus cases as of August 31, 2025, which increases the risk of diabetic foot ulcers, delayed wound healing, and infection-related complications.
Chronic wound care demand is rising because diabetes monitoring remains limited among many patients. In 2025, only 44.02% of Colombian diabetes patients had an HbA1c measurement in the previous six months, which may increase the risk of uncontrolled diabetes and non-healing wounds.
Biologic wound care products are gaining importance as hospitals look for faster tissue repair and wound closure options. INVIMA classified EPIFAST as a biological dressing and human-tissue allograft, showing formal regulatory relevance for tissue-based wound healing products in Colombia.
Market Segmentation
By Product Type (Revenue, USD Mn, 2021-2033)
Biologic Skin Substitutes
Enzyme Based Formulations
By Application (Revenue, USD Mn, 2021-2033)
Chronic Wounds
Diabetic Foot Ulcer
Venous Leg Ulcer
Pressure Ulcer
Acute Wounds
Surgical Wounds
Burns
By End User (Revenue, USD Mn, 2021-2033)
Hospitals
Clinics
Ambulatory Surgical Centers
Home Care Settings
Sources
Primary Research Interviews
Wound Care Biologics Manufacturers
Biologic Skin Substitute Manufacturers
Advanced Wound Care Product Manufacturers
Collagen Dressing and Enzyme-Based Formulation Suppliers
Growth Factor Therapy Providers
Hospitals and Wound Care Clinics in Colombia
Diabetic Foot Care Specialists
Burn Care Specialists and Plastic Surgeons
Dermatologists and Vascular Surgeons
Medical Device Distributors and Importers in Colombia
Tissue Banks and Regenerative Medicine Experts
Hospital Procurement Managers
Others
Databases
Bloomberg Terminal
Thomson Reuters Eikon / Refinitiv
IQVIA
GlobalData Medical Intelligence
S&P Global Market Intelligence
D&B Hoovers
UN Comtrade Database
World Bank Open Data
OECD Health Statistics
SISPRO – Integrated Social Protection Information System, Colombia
INVIMA Product and Registration Databases
Others
Magazines
WoundSource
Today’s Wound Clinic
Wounds International
Wound Care Learning Network
Medical Device Network
MedTech Dive
Healthcare Global
Latin America Healthcare Business
Others
Journals
Wound Repair and Regeneration
International Wound Journal
Journal of Wound Care
Advances in Skin & Wound Care
Diabetes Care
International Journal of Lower Extremity Wounds
Burns
Journal of Tissue Engineering and Regenerative Medicine
Stem Cells Translational Medicine
Others
Newspapers
Reuters
Bloomberg News
Financial Times
The Wall Street Journal
El Tiempo
Portafolio
La Republica
Semana
Others
Associations
Asociacion Colombiana de Diabetes
Asociacion Colombiana de Dermatologia y Cirugia Dermatologica
Asociacion Colombiana de Cirugia
Sociedad Colombiana de Cirugia Plastica Estetica y Reconstructiva
Asociacion Colombiana de Hospitales y Clinicas
International Working Group on the Diabetic Foot
European Wound Management Association
Wound Healing Society
International Society for Burn Injuries
Others
Public Domain Sources
INVIMA – Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Ministerio de Salud y Proteccion Social, Colombia
SISPRO – Sistema Integral de Informacion de la Proteccion Social
DANE – Departamento Administrativo Nacional de Estadistica
World Bank Open Data
Pan American Health Organization
World Health Organization
International Diabetes Federation
U.S. FDA Medical Devices Database
European Medicines Agency
ClinicalTrials.gov
Others
Proprietary Elements
CMI Data Analytics Tool
Proprietary CMI Existing Repository of Information for the Last 10 Years
Share
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
The Colombia Wound Care Biologics Market is expected to reach USD 29.5 Mn in 2033.
Major players operating in the global Colombia Wound Care Biologics Market include Smith & Nephew, Plc, Organogenesis, Inc., Integra Life Sciences Corporation, MiMedx Group, Inc., Skye Biologics, Inc., Amino Technology LLC, Osiris Therapeutics, Inc., Alphatec Holdings, Inc. Mallinckrodt Plc., Amniox Medical, Inc., Acelity L.P. Inc., ConvaTec Group Plc, Generex Biotechnology Corporation, and Olaregen Therapeutix Inc.
The high price of advanced skin substitutes, a preference for cheaper traditional dressings, and a shortage of specialized professionals for applying complex biologics are the key factors hampering growth of the market.
The rising diabetic foot ulcer cases, a rapidly aging population, increasing adoption of advanced skin substitutes, and improved access to healthcare, particularly for chronic wound management is boosting demand for wound care biologics.
The Colombia Wound Care Biologics Market is anticipated to grow at a CAGR of 10.2% between 2026 and 2033.
Among product type, the biologic skin substitutes segment is expected to account for a largest market share in the Colombia Wound Care Biologics Market over the forecast period.
Wound care biologics are advanced therapies derived from natural living organisms—such as human, animal, or microbial tissues—used to accelerate healing in complex, chronic, or non-healing wounds.
